EMA Authorised: Olazax Disperzi (olanzapine) — Glenmark Pharmaceuticals s.r.o.

View source ↗

Summary

Authorised olazax disperzi (olanzapine) for schizophrenia and bipolar disorder in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Schizophrenia

Drugs mentioned

• Olazax Disperzi (olanzapine)

Snippet

Status: Authorised. Therapeutic area: Schizophrenia;Bipolar Disorder. MAH: Glenmark Pharmaceuticals s.r.o.. Decision date: 16/03/2020